MyMD Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Morison Cogen LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +7.31% | -6.00% | -69.72% |
Apr. 18 | MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer | CI |
Apr. 09 | Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data | MT |
1st Jan change | Capi. | |
---|---|---|
-69.72% | 5.07M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MYMD Stock
- News MyMD Pharmaceuticals, Inc.
- MyMD Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt